Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 15/20 | 0.72 |
| ▸ | BCL2 | P10415 | 14/20 | 0.53 |
| ▸ | BAD | Q92934 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19263461 | 0.92 | BCL2L1 (0.84) | BCL2L1BCL2BAD | |
| SCHEMBL30405101 | 0.91 | BCL2L1 (0.85) | BCL2L1BCL2 | |
| SCHEMBL31570836 | 0.91 | BCL2L1 (0.85) | BCL2L1BCL2 | |
| SCHEMBL24633503 | 0.90 | BCL2L1 (0.87) | BCL2L1BCL2 | |
| SCHEMBL22879158 | 0.90 | BCL2L1 (0.87) | BCL2L1BCL2 | |
| SCHEMBL29424547 | 0.90 | BCL2L1 (0.87) | BCL2L1BCL2 | |
| SCHEMBL20305899 | 0.89 | BCL2L1 (0.66) | BCL2L1BCL2 | |
| SCHEMBL19145119 | 0.85 | BCL2L1 (0.84) | BCL2L1BCL2BAD | |
| SCHEMBL25423839 | 0.84 | BCL2L1 (0.94) | BCL2L1BCL2 | |
| SCHEMBL25423836 | 0.84 | BCL2L1 (0.94) | BCL2L1BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9737535-B2 | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-08-22 | — | — | US | disclosed |